Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Irene Robinson

  • Home
  • Author: Irene Robinson

COVID-19 disruption of clinical trials varies by therapy area

The number of clinical trials disrupted by the COVID-19 pandemic continues to increase into 2021, although the degree of disruption varies depending on the therapy area, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, MPH, Senior Analyst at GlobalData, comments: “Companies and organizations continue to report trial disruptions due to the COVID-19 pandemic, including delayed initiation, delayed enrollment, and slow enrollment, although not all therapy areas have been equally affected.” Comparing April 2020 […]
Read more

The COVID-19 pandemic is driving an increase in novel FDA approvals and outsourcing of manufacturing

Innovative drug approvals increased in the US between 2019 and 2020. This increase happened despite the FDA’s stretched resources, as it had to reassign staff to cope with COVID-19-related activities. The agency approved 121 novel drugs in 2020, compared with 119 in in 2019, says GlobalData, a leading data and analytics company. Adam Bradbury, PharmSource Analyst at GlobalData comments: “There was a large increase in approvals of new molecular entities (NMEs), the most innovative drug type with 21% more NME approvals than in 2019. There were also more small cap pharma–sponsored drug approvals and overall approvals compared […]
Read more

Addressing ESG issues may help pharma to repair its reputation

As pharmaceutical companies continue to grapple with issues ranging from lack of transparency on pricing, price gouging to questionable ethical practices and clinical data reporting processes, addressing environmental, social, and governance (ESG) issues will continue to be an important, and perhaps beneficial theme for the industry in 2021, says GlobalData a leading data and analytics company. In a recent GlobalData poll* it was highlighted that environmental issues were viewed as the most important ESG area […]
Read more

Bio/Pharma companies’ Q4 2020 market performance impacted by development of treatments or vaccines for COVID-19

The market performance of the top 20 Bio/Pharma companies is still being impacted by the COVID-19 pandemic, either positively for companies developing a vaccine for the disease or negatively for those working on a treatment, says GlobalData, a leading data and analytics company. Madeleine Roche, MSc, Analyst at GlobalData comments: “Drug sales for Q4 2020 heavily influenced company performance, with COVID-19 vaccines driving market cap growth, but COVID-19 therapeutics possibly causing a decline. The top 10 companies (Johnson & Johnson, F. Hoffmann-La Roche, Novartis, Merck & Co, Pfizer, AbbVie, Eli […]
Read more

Israel’s COVID-19 vaccine rollout highlights protection data in real time

Following the news from Israel that Pfizer and BioNTech’s COVID-19 vaccine reduced symptomatic SARS-CoV-2 by 94% and severe COVID-19 by 92%; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers their view: “The speedy rollout of Pfizer and BioNTech’s vaccine in Israel creates real world data almost in real time on the public health outcomes of COVID-19 vaccination, serving as an example for the rest of the world. A combination of a highly effective vaccine, […]
Read more

Caladrius Biosciences’ US sales of CLBS16 in CMD to reach $346m by 2028, despite market entry hurdles

Caladrius Biosciences’ initiation of the Phase IIb FREEDOM trial of its autologous CD34+ stem cell therapy, CLBS16, in coronary microvascular dysfunction (CMD), is an important development milestone. While concerns regarding the therapy’s scalability, potential cost and durability of the treatment effect will impact its market uptake, the drug is forecast to generate US sales of $364m by 2028, according to GlobalData, a leading data and analytics company. Kelly Lambrinos, Managing Analyst at GlobalData, comments: “There are no drugs that specifically […]
Read more

Positive COVID-19 test rates by age group must be monitored as the vaccination campaign continues in the UK

COVID-19 cases and deaths in the UK have finally started to decrease after the country entered into the third national lockdown at the beginning of January. As the UK looks to re-open its economy, monitoring age-specific rates is vital to prevent a further resurgence of cases before the national vaccination program is complete, says GlobalData, a leading data and analytics company. Approximately 68,000 new cases of COVID-19 were recorded on January 8, 2021, which is the highest daily total the country has seen since the pandemic began. […]
Read more

Directed energy weapons demand set to surge among military forces

Directed energy weapons (DEWs) have finally reached top power levels and the effectiveness to allow them to be used on the battlefield. Combat platforms are expected to be equipped with DEWs by 2025, working alongside conventional weapons such as guns and missiles, according to GlobalData, a leading data and analytics company. Military forces are seeking to launch and deploy effective DEWs at the earliest opportunity and demand is surging as the global value for DEWs […]
Read more

Biden and Democrats to tackle COVID-19 logistics, not regulatory processes

With Joe Biden ascending to the presidency with a Democrat-controlled Congress, COVID-19 is expected to take center stage in this administration. Biden unveiled a $1.9 trillion stimulus package aimed at supporting vaccine distribution efforts, as well as additional direct deposits to eligible Americans. Although the new administration is unlikely to have a direct impact on the regulatory processes for additional COVID-19 vaccines and therapeutics, they have taken several measures to ensure a smooth transition on the logistical front, […]
Read more

COVID-19 disrupted clinical trials due to slow recruitment continue to grow

Since June 2020, the number of total disrupted trials has been falling slowly; however, this has leveled off in October 2020. Despite this, the number of clinical trials that have resumed continues to rise. The majority of current trial disruptions are due to trials impacted by slow enrollment, which continue to gradually increase, says GlobalData, a leading data and analytics company. Brooke Wilson, Associate Director, Trials Intelligence at GlobalData, comments: “This implies that although sponsors and contract service […]
Read more

Severe COVID-19 survivors may face an increased risk of developing dementia

Brain inflammation and mini-strokes observed in COVID-19 patients may place them at increased risk of developing Alzheimer’s disease (AD) and other types of dementia. For COVID-19 survivors, adverse cognitive outcomes may be long term and result in lower quality of life and disability, particularly among severe cases, says GlobalData, a leading data and analytics company. Ana Fernandez-Menjivar, Pharma Analyst at GlobalData, comments: “Some of the most concerning lasting effects of COVID-19 are continued loss of sense of smell or taste, memory or concentration problems, and other cognitive complications, because they indicate probable […]
Read more

Across pharmaceutical value chain drug development process will experience biggest impact from COVID-19 in 2021

Despite seriously affecting the ability to carry out clinical research, COVID-19 is also proving to be a catalyst that may transform the drug development process, with technological innovations taking center stage in driving this change, says GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry 2021’, reveals that the drug development process will face the biggest impact from COVID-19 in 2021, as confirmed by 32% (N=63) out of 198 pharmaceutical industry professionals. […]
Read more

Sentiment towards technology warms as COVID-19 forces businesses to go digital

The COVID-19 pandemic has led to an increase in positive sentiment towards technology, as 57% of respondents to GlobalData’s poll stated that their attitude towards cybersecurity had become more positive in 2020. A further 53% of respondents were equally positive about cloud computing. Reliance on cloud computing for storage and collaboration has been a feature of the pandemic, according GlobalData, a leading data and analytics company. GlobalData’s report, […]
Read more

Xeljanz safety data in Rheumatoid Arthritis could mean headaches for all JAK inhibitors

Following Pfizer’s recent announcement of co-primary endpoint results from ORAL Surveillance (NCT02092467) in rheumatoid arthritis (RA) patients with cardiovascular (CV) risk factors; Rose Joachim, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “These results signal troubles ahead for Xeljanz and potentially other JAK inhibitor products. The ORAL Surveillance trial first came under scrutiny in early 2019, when Pfizer had to modify the protocol […]
Read more

Life and health insurance most likely products to see long-term benefits from COVID-19

The life and health insurance markets will see the most positive impact from the COVID-19 pandemic, according to a GlobalData poll. The pandemic has caused major disruption to a myriad of businesses, resulting in some insurance lines seeing huge declines in business, but some products may also benefit in the longer term. Respondents to GlobalData’s poll indicated that life and health products would see the most positive impact. Consumers and businesses are likely to feel more vulnerable to viruses and want more protection in the form of such policies. Ben Carey-Evans, Analyst at GlobalData, comments: “Business interruption insurance is […]
Read more
1 2 3 … 15